Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DURHAM, N.C., May 16, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, recently presented data demonstrating CMX001’s high barrier to viral resistance in the prevention and treatment of cytomegalovirus (CMV) infection. The data were presented at the International Society for Antiviral Research’s 26th International Conference on Antiviral Research (ICAR) held May 11-15, 2013 in San Francisco, CA. CMX001 is an investigational oral nucleotide analog lipid-conjugate that has a broad spectrum of antiviral activity against double-stranded DNA (dsDNA) viruses.
Help employers find you! Check out all the jobs and post your resume.
